Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alterity Therapeutics Limited - Sponsored ADR (ATHE : NSDQ)

• Company Description    Alterity Therapeutics Limited is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset consists ATH434, to treat various Parkinsonian disorders. Alterity Therapeutics Limited, formerly known as PRANA BIO, is based in MELBOURNE, Australia. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $4.61 Daily Weekly Monthly 20 Day Moving Average: 67,608 shares Shares Outstanding: 8.87 (millions) Market Capitalization: $40.88 (millions) Beta: 0.71 52 Week High: $5.87 52 Week Low: $1.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.22% 0.88% 12 Week 30.23% 13.42% Year To Date 39.28% 30.08%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Level 14 350 Collins Street - Melbourne,C3 VIC 3000 AUS ph: 61-0-3-9349-4906 fax: 61-3-9348-0377 we-aualterity@we-worldwide.com https://alteritytherapeutics.com

• General Corporate Information    Officers David A. Stamler - Chief Executive Officer Geoffrey Kempler - Chairman Phillip Allen Hains BBus - Company Secretary and Chief Financial Officer Lawrence B. Gozlan - Director Peter A. Marks - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 02155X205 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 8.87 Most Recent Split Date: 1.00 (0.10:1) Beta: 0.71 Market Capitalization: $40.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.06 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 3.84 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 0.57 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©